Skip to main content
Indaptus Therapeutics, Inc. logo

Indaptus Therapeutics, Inc. — Investor Relations & Filings

Ticker · INDP ISIN · US45339J1051 US Professional, scientific and technical activities
Open in API
Filings indexed 300 across all filing types
Latest filing 2026-05-15 Interim / Quarterly Rep…
Country US United States of America
Listing US INDP

About Indaptus Therapeutics, Inc.

https://indaptusrx.com/

Indaptus Therapeutics, Inc. is a clinical-stage biotechnology company that develops immunotherapies for cancer and viral infections. The company's proprietary platform is based on a patented approach that uses engineered, attenuated, and killed non-pathogenic gram-negative bacteria to activate the immune system. This technology, known as Decoy20, is designed to harness the natural ability of bacteria to engage both innate and adaptive immune pathways. By systemically administering these agents, Indaptus aims to stimulate a broad immune response against tumors and virally infected cells. The company's approach has demonstrated anti-tumor and anti-viral activity in pre-clinical models.

Recent filings

Filing Released Lang Actions
10-Q
Interim / Quarterly Report Q1 2026
2026-05-15 English
8-K
Report Publication Announcement Classification · 91% confidence The document is a US SEC Form 8-K current report whose sole substantive content is to furnish and announce a press release containing the company’s quarterly financial results (Item 2.02). No actual financial data or earnings highlights are included in the text—only an Exhibit reference to the press release. Under the “menu vs. meal” rule, this is an announcement of the publication of another report (the earnings press release), not the report itself. Therefore, it best fits the Report Publication Announcement category (RPA).
2026-05-15 English
8-K - Indaptus Therapeutics, Inc. (0001857044) (Filer)
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content specifically details the appointment of new independent directors to the Board of Directors, their qualifications, committee appointments, and the resignation of a director. There is no financial data or earnings information, nor is it an annual or quarterly report. The focus is on changes in the company's board and management structure. Therefore, this document fits the category of Board/Management Information (MANG). The document length (8554 characters) supports it being a full report rather than a brief announcement or certification.
2026-04-23 English
8-K - Indaptus Therapeutics, Inc. (0001857044) (Filer)
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The key content includes the resignation of a CFO, appointment of a new CFO, appointment of a new director, and changes in the Audit Committee. These are all changes in the company's board of directors and senior management. There is no financial data or detailed financial results presented, so it is not an Annual Report, Interim Report, or Earnings Release. The document is not a proxy statement or voting results announcement. The primary focus is on management and board changes, which fits the Board/Management Information category (MANG). The document length is 7005 characters, which is sufficient for a detailed announcement rather than a brief notice. Therefore, the correct classification is MANG with high confidence.
2026-04-03 English
4 - Indaptus Therapeutics, Inc. (0001857044) (Issuer)
Director's Dealing
2026-03-24 English
4 - INDAPTUS THERAPEUTICS, INC. (0001857044) (Filer)
Director's Dealing
2026-02-27 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.